iShares Core MSCI China Index ETF(02801.HK) Fell 1.31% to 25.540
Newtimespace News, as of 10:51 on May 15, iShares Core MSCI China Index ETF(02801.HK) was quoted at HKD 25.540, down 1.31%. The ETF opened at HKD 25.860, with a high of HKD 25.860 and a low of HKD 25.480. The latest Net Asset Value (NAV) per unit is HKD 25.825, with a premium rate of 0.21%. The asset size is approximately HKD 16.045 billion.
iShares Core MSCI China Index ETF(02801.HK) tracks the MSCI China Index, which is compiled and published by the international index provider MSCI Inc. The index aims to measure the performance of large and mid-cap companies in the Chinese stock market. It is a key component of the MSCI Emerging Markets Index and serves as one of the core benchmarks for global investors allocating to Chinese assets.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- VSING (08292.HK): Proposes Acquisition of Equity Interest in Golfzon Hong Kong to Build "Technology + Sports + Social" Entertainment Experience
- HK SH ALLIANCE (01001.HK): Subsidiary Unsuccessful in Tender for Tsing Yi Advanced Construction Industry Building Project
- BAIYUNSHAN PH (00874.HK): Dexamethasone Sodium Phosphate Injection (1ml:5mg) of Controlled Subsidiary Passes Generic Consistency Evaluation
- CI FIN TECH GP (08029.HK): Executive Director Wang Qiang Appointed Chairman of the Board; Zheng Meicheng Appointed Vice-chairwoman
- Shaanxi Micot Pharmaceutical Technology Co., Ltd (02335.HK): Phase II Clinical Study of Dual-Function Antithrombotic Candidate MT1002 for Anticoagulation in Haemodialysis Completes First Patient Enrolment